In a recent legal development, a Texas judge has dismissed a request from the state’s Attorney General, Ken Paxton, to immediately halt Tylenol advertisements by its maker, Kenvue, amid ongoing litigation questioning the safety of the medication for pregnant women and children. The lawsuit, centered on the unproven assertion that Tylenol might lead to autism, has sparked controversy.
The rejection by District Judge LeAnn Rafferty in Panola County not only denied Paxton’s plea for a temporary restraining order against Kenvue’s safety claims but also turned down a request to prevent the company from distributing substantial dividends to shareholders. These decisions mark initial setbacks for Paxton in a case intertwined with political implications and medical controversies.
The claim linking Tylenol to autism was initially promoted by former President Trump and Robert F. Kennedy Jr., despite lacking scientific validation. While some studies have suggested a potential association between Tylenol use and autism, the evidence remains inconclusive and flawed, with other research finding no such correlation. Notably, acetaminophen, the active ingredient in Tylenol, is widely regarded as a safe pain and fever relief option for pregnant individuals, with untreated pain and fevers posing risks, including an elevated likelihood of autism.
Despite the absence of conclusive evidence linking Tylenol to autism, Paxton’s lawsuit against Kenvue and its former parent company, Johnson & Johnson, alleges deceptive marketing practices, demanding changes in Tylenol’s promotional strategies and financial penalties.
Source: Ars Technica